Results 11 to 20 of about 13,843 (217)

Case Report: Successful management of refractory palmoplantar pustulosis with upadacitinib [PDF]

Frontiers in Immunology
Palmoplantar Pustulosis (PPP) is a rare chronic skin disorder characterized by recurrent sterile pustules on palms and soles, leading to significant pain and functional impairment. Treatments include topical medications, phototherapy, systemic treatments,
Wang Huiying
exaly   +5 more sources

Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients [PDF]

Frontiers in Medicine
BackgroundUpadacitinib, a specific JAK1 inhibitor, has minimal effect on other JAK subtypes. It influences the inflammatory process in various ways. Upadacitinib has been approved for conditions such as rheumatoid arthritis, psoriatic arthritis, atopic ...
Na Du, Jingyi Yang, Yiwen Zhang, Xinyan Lv, Lei Cao, Lei Cao, Lei Cao, Wei Min   +7 more
exaly   +5 more sources

Palmoplantar Pustulosis: A Case Report [PDF]

Clinical Practice and Cases in Emergency Medicine, 2020
Introduction: Dermatology complaints account for 3.3% of emergency department (ED) visits per year. Most rashes are benign, but there are a select few that emergency physicians must be familiar with as delay in treatment could be life threatening.
Anne Dulski, Vince Varamo
doaj   +6 more sources

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial. [PDF]

J Eur Acad Dermatol Venereol
In this Phase 3 trial of Japanese patients with moderate to severe PPP (NCT05174065), significantly more patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo. Patient‐reported outcomes, including pruritus and pain/discomfort, also showed significantly greater decreases at Week 16 with apremilast versus placebo.
Terui T, Okubo Y, Kobayashi S, Morita A, Imafuku S, Tada Y, Abe M, Strober B, Gooderham M, Zhang W, Shimauchi J, Yaguchi M, Kimura T, Ogawa R, Amouzadeh H, Murakami M.   +15 more
europepmc   +3 more sources

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68-week randomized Phase 3 trial. [PDF]

J Eur Acad Dermatol Venereol
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Murakami M, Okubo Y, Kobayashi S, Kikuta N, Ouchi Y, Shishido K, Terui T.   +6 more
europepmc   +3 more sources

JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review [PDF]

Drugs in Context
Background: Palmoplantar pustulosis (PPP) is a chronic, relapsing skin condition characterized by sterile, pruritic pustules on erythematous, thickened skin of the palms and soles.
Beatriz Henriques dos Santos, João Domingues, Marco Sousa, Tiago Torres   +3 more
doaj   +3 more sources

Case Report: Successful treatment of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome and palmoplantar pustulosis with ustekinumab [PDF]

Frontiers in Immunology
Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a rare chronic inflammatory disease mainly manifested as skin and osteoarticular lesions.
Luxia Chen, Qichang Liang, Sijia Chen, Hao Cheng   +3 more
doaj   +3 more sources

Topical Crisaborole for the Treatment of Recalcitrant Palmoplantar Pustulosis: A Case Series [PDF]

Dermatology and Therapy
Palmoplantar pustulosis (PPP) is a chronic, relapsing disease with sterile pustules involving the palms and soles. The pathogenesis of PPP remains unclear and there is currently no standard treatment.
Yen-Yi Sung, Tsen-Fang Tsai
doaj   +3 more sources

Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT) trial protocol [PDF]

BMJ Open
Background Palmoplantar pustulosis (PPP) is a rare, debilitating inflammatory skin disease involving painful pustules on the palms and soles. Janus kinase (JAK) inhibitors target pathways relevant to PPP disease biology but also confer a risk of major ...
Weiyu Ye, Suzie Cro, James B Galloway, Sarah Chapman, C H Smith, Kingsley Powell, Jonathan Barker, Ann Naylor, Helen McAteer, John Gregory, David Gleeson, April Qin, Jade Pizzato, Manpreet K Sagoo, Lucy Moorhead, Andrew E Pink, Richard Woolf, Satveer K Mahil   +17 more
doaj   +3 more sources

Extra-Palmoplantar Lesions of Palmoplantar Pustulosis: Underrecognized but Important Manifestation

Indian Journal of Dermatology
Background: Patients with palmoplantar pustulosis (PPP) rarely develop scaly erythematous and/or pustular lesions on sites other than the palms and soles, such as the dorsa of the feet, lower legs, knees, elbows, buttocks and trunk.
Toshiyuki Yamamoto
doaj   +3 more sources